Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah E Smith

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
The Lancet. Microbe|January 12, 2026
SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studiesMelisa M Shah, Glen R Abedi, Scott Lu, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery, SAR, and X-ray Binding Mode Study of BCATm Inhibitors from a Novel DNA-Encoded LibraryHongfeng Deng, Jingye Zhou, Flora S Sundersingh, et al.
Journal of Medicinal Chemistry|June 20, 2015
The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS HitsSophie M Bertrand, Nicolas Ancellin, Benjamin Beaufils, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2014
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosisJ Peter Cegielski, Tracy Dalton, Martin Yagui, et al.
Emerging Infectious Diseases|July 21, 2021
Effects of Patient Characteristics on Diagnostic Performance of Self-Collected Samples for SARS-CoV-2 TestingSarah E Smith-Jeffcoat, Mitsuki Koh, Adam Hoffman, et al.
The Lancet. Respiratory Medicine|March 2, 2015
Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studiesEkaterina V Kurbatova, J Peter Cegielski, Christian Lienhardt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2023
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated IndividualsSarah E Smith-Jeffcoat, Jessica E Biddle, H Keipp Talbot, et al.
JAMA Internal Medicine|January 6, 2026
Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024Emilia H A Koumans, Diba Khan, Imelda Trejo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug ResistanceJ Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, et al.
MMWR. Morbidity and Mortality Weekly Report|February 17, 2022
Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention - New York City, November-December 2021Samira Sami, Libby Horter, Diana Valencia, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
The Lancet. Microbe|January 12, 2026
SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studiesMelisa M Shah, Glen R Abedi, Scott Lu, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery, SAR, and X-ray Binding Mode Study of BCATm Inhibitors from a Novel DNA-Encoded LibraryHongfeng Deng, Jingye Zhou, Flora S Sundersingh, et al.
Journal of Medicinal Chemistry|June 20, 2015
The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS HitsSophie M Bertrand, Nicolas Ancellin, Benjamin Beaufils, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2014
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosisJ Peter Cegielski, Tracy Dalton, Martin Yagui, et al.
Emerging Infectious Diseases|July 21, 2021
Effects of Patient Characteristics on Diagnostic Performance of Self-Collected Samples for SARS-CoV-2 TestingSarah E Smith-Jeffcoat, Mitsuki Koh, Adam Hoffman, et al.
The Lancet. Respiratory Medicine|March 2, 2015
Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studiesEkaterina V Kurbatova, J Peter Cegielski, Christian Lienhardt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2023
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated IndividualsSarah E Smith-Jeffcoat, Jessica E Biddle, H Keipp Talbot, et al.
JAMA Internal Medicine|January 6, 2026
Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024Emilia H A Koumans, Diba Khan, Imelda Trejo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug ResistanceJ Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, et al.
MMWR. Morbidity and Mortality Weekly Report|February 17, 2022
Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention - New York City, November-December 2021Samira Sami, Libby Horter, Diana Valencia, et al.
Pageof 13